In the following interview, co-author and panel member Benjamin M. Brucker, MD, provides a detailed walkthrough of these guidelines and discusses their practical implications for clinicians.He ...

The combination of zanzalintinib and nivolumab (Opdivo) showed promising efficacy and manageable safety in previously untreated stage 4 renal cell carcinoma (RCC), with a 63% response rate and ...

The survey examines urologists' treatment patterns and preferences for non–muscle invasive bladder cancer, providing valuable insights into current practices. Michael S. Cookson, MD, and Jason M.

First-line nivolumab (Opdivo) plus ipilimumab (Yervoy) continued to show improved survival and durable response benefits vs sunitinib (Sutent) in patients with previously untreated advanced renal cell ...

Results of subgroup analyses of the phase 3 CREST trial (NCT04165317) evaluating sasanlimab plus BCG compared with BCG alone in patients with high-risk non–muscle invasive bladder cancer (NMIBC) found ...

A recent study by Moyer et al (2025) provides real-world data on the efficacy and safety of nadofaragene firadenovec in patients with BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC).

GSK and Spero Therapeutics announced that the pivotal phase 3 PIVOT-PO trial (NCT06059846) of tebipenem pivoxil hydrobromide (HBr) for complicated urinary tract infection (cUTI) has been stopped early ...

The ODAC meeting was called to discuss the submitted new drug application (NDA) for UGN-102, which the agency previously accepted in October 2024, issuing a Prescription Drug User Fee Act (PDUFA) ...

The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted in a unanimous 0-8 decision that the TALAPRO-2 data on talazoparib (Talzenna) in combination with enzalutamide (Xtandi) is not sufficient to ...

Data from the AUSCO trial (NCT04088331) were presented at the 2025 American Urological Association Annual Meeting in Las Vegas, Nevada, showing that the artificial urinary sphincter (AUS) demonstrated ...

A recent study examined the relationship between randomized controlled trials and real-world efficacy of prostate cancer treatments. 1 Investigators found that benefits of treatments that are observed ...

At this year’s American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada, the AUA released their new guideline on genitourinary syndrome of menopause in collaboration with the Society ...